Aethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study

Aethlon will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV)

SAN DIEGO, Dec. 11, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier® therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas. The study, which will enroll individuals infected with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device Exemption (IDE) approved by the United States Food and Drug Administration (FDA). A detailed description of the study, including treatment protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov.

The Aethlon Hemopurifier is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. To date, Hemopurifier therapy has been administered outside the United States in the treatment of Ebola, HIV and HCV-infected individuals.

Under the feasibility study protocol, Aethlon will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy in an infectious disease model. Upon successful completion of the feasibility study, Aethlon plans to conduct pivotal efficacy studies required for market clearance to treat chronic viral indications. 

Read complete press release here...

Labels: , ,